王群光自然診所：台北市羅斯福路三段271號10樓諮詢電話：886-2-23671086LINE ID：0919730053 Wechat ID： a0919730053
Wechat ID： a0919730053
Are the effects of α-glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract?
Received 20 April 2009;
revised 28 May 2009;
accepted 31 May 2009.
Available online 8 June 2009.
AbstractThe major side-effect of treatment with α-glucosidase inhibitors, flatulence, occurs when undigested carbohydrates are fermented by colonic bacteria, resulting in gas formation. We propose that the cardiovascular benefits of α-glucosidase inhibitors are partly attributable to their ability to neutralise oxidative stress via increased production of H2 in the gastrointestinal tract. Acarbose, which is an α-glucosidase inhibitor, markedly increased H2 production, with a weaker effect on methane production. Our hypothesis is based on our recent discovery that H2 acts as a unique antioxidant, and that when inhaled or taken orally as H2-dissolved water it ameliorates ischaemia–reperfusion injury and atherosclerosis development.
Keywords: α-Glucosidase inhibitors; Type 2 diabetes; Hydrogen gas; Antioxidant
Fig. 1. Effects of acarbose on the levels of exhaled H2 and CH4. The values shown in the bar graphs are means ± S.D.
Eleven healthy volunteers (10 males and 1 female) were administered acarbose at a dosage of 300 mg/day (100 mg three times a day) for 4 days under free-feeding conditions. Exhaled gas was collected in an aluminium bag at the point of mid-expiration at the indicated time-points (i.e., morning, before lunch, 2 h after lunch, before retiring), both before and after acarbose treatment. The exhaled gas samples were injected into the Breath Gas Analyzer to measure the H2 and CH4 concentrations.
Corresponding author. Address: Department of Regenerative Medicine and Advanced Cardiac Therapeutics, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan. Fax: +81 3 5363 3875.